Zynerba Pharmaceuticals Announces Initiation of STAR 2 Open …

DEVON, Pa., Nov. 02, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the enrollment of the first patients into the STAR 2 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, an open-label extension trial which allows patients who have completed  the STAR 1 clinical trial to receive treatment with ZYN002 CBD gel for up to 52 weeks.

“STAR 2 is designed to provide additional tolerability and safety information for ZYN002 CBD gel for up to 52 weeks, which we believe will establish that ZYN002 CBD gel is well-tolerated over long-term use,” said Armando Anido, CEO of Zynerba. “Enrollment in STAR 1 is continuing and we plan to report top line results in the first half of 2017.” 

STAR 2 is a multi-center, open-label

... read more at: http://globenewswire.com/news-release/2016/11/02/885601/0/en/Zynerba-Pharmaceuticals-Announces-Initiation-of-STAR-2-Open-Label-Extension-Clinical-Trial-for-ZYN002-CBD-Gel-in-Adult-Refractory-Epilepsy-Patients.html

by